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PAR2 in viral infections

Silvio Antoniak PhD
There is a known interaction between the blood coagulation and innate immune system partly mediated by proteaseactivated receptors (PARs). 1 During viral infection, pathogen and host-derived proteases including known PAR2 activators are generated. Importantly, we and others showed that PAR2 dampens antiviral interferon β (IFNβ) but increases NFκB responses after viral infections. [1] [2] [3] In viral myocarditis, cardiac PAR2 inhibits IFNβ responses during Coxsackievirus B3 virus infection causing increased cardiac virus load and inflammation and subsequently increased cardiac injury. 2 In addition, we and others found that PAR2 increases H1N1 influenza A virus (IAV) pathology. 3 Recent findings suggest that myeloid cell (possibly macrophage) and lung epithelial cell PAR2 contribute to IAV pathology. Preliminary data showed that PAR2 activation leads to increased CXCL1 expression and neutrophil infiltration into the lung and subsequently causing endothelial cell (EC) and epithelial cell (EPC) injury. The current data suggest a potential therapeutic strategy by blocking the pathologic PAR2 signaling pathway to improve the outcome and severity of virus infections.
Polyphosphate complements coagulation
Edward M. Conway MD, PhD
In response to injury, platelets (plts) and endothelial cells (ECs) are activated, causing polyphopshate (polyP) and C1-esterase inhibitor (C1-INH) to colocalize on the cells. PolyP triggers coagulation via activation of factors XII and XI to XIIa and XIa, respectively (1a), leading to thrombin (IIa) generation and clot formation 4 (1b) . XIIa also converts prekallirein (PK) to kallikrein (K), which yields more XIIa and bXIIa.
Activated platelets and endothelial cells also trigger complement activation (2a), promoting assembly of C3 and C5 convertases, which lead to formation of C5b,6 and the C5b-9 membrane attack complex (MAC). bFXIIa also contributes by activating complement factors C1r and C1s (2b).
If unchecked, complement activation results in autoimmune destruction of the activated endothelial cells and platelets, abrogating their procoagulant functions. PolyP prevents this by potentiating the inhibitory properties of C1-INH, such that it neutralizes C1r and C1s (3a), and destabilizes C5b,6 6 (3b), reducing MAC formation.
Von Willebrand disease type 2B: an ever surprising condition
Cécile V. Denis PhD
Von Willebrand disease type 2B (vWD-type 2B) is a counterintuitive pathological condition in which gain-of-function mutations in the plasma protein von Willebrand factor (VWF) lead to a bleeding rather than a prothrombotic phenotype. For the most severe mutations, underlying molecular mechanisms involve: (1) defective platelet function due to impaired signaling leading to lack of activation of αIIbβ3 integrin 7 and (2) thrombocytopenia of various severity. This thrombocytopenia originates from a central production defect 8 as well as from an increased clearance of platelets from the circulation. 9 How mutations in VWF can induce such a variety of cellular effects is currently under investigation. Interestingly, strategies aiming to restore a normal platelet count such as thrombopoietin receptor agonists or LIM kinase inhibitors may be beneficial in some patients with vWDtype 2B.
Novel hemophilia therapeutics Lindsey A. George MD
Novel therapeutics for hemophilia are poised to alter the current treatment paradigm. Traditional factor-replacement has normalized the life expectancy of hemophilia patients. However, several aspects remain suboptimal, including the need for recurrent intravenous administration and thus significant planning, and the risk of alloantibody formation. Current novel therapeutics include successful early-phase adeno-associated virus-mediated factor VIII and IX gene transfer, a FVIII-mimetic antibody (emicizumab) and strategies to disrupt natural anticoagulants, including tissue factor pathway inhibitory (TFPI) antibodies, an activated protein C (APC) serpin, and RNAi knock-down of antithrombin III (ATIII) with fitusiran. 10-15 Importantly, these new agents can be administered subcutaneously and/or at a reduced frequency. However, thrombotic complications and deaths reported in clinical trials with emicizumab and fitusiran highlight the importance of bridging science with clinical care to ensure safe adaptation. Nonetheless, this expanding therapeutic repertoire provides an optimistic outlook for the future of hemophilia care. release from both of these cell types (3). Platelet-and RBC-derived MVs are also generated in red cell and platelet units for transfusion during blood bank storage (4). RBC-MVs and PLT-MVs activate the contact system (5). Unlike histones, nucleosomes or intact NETs, free DNA directly triggers contact activation (6) . The activated form of factor XII (FXIIa) is generated following contact activation. FXIIa may promote activation of factor XI (7), which mediates downstream thrombin generation (8) . 
Cellular products and contact activation
Specificity and function in thrombin and the products of prothrombin activation
Sriram Krishnaswamy PhD
The cleavage of prothrombin to thrombin is required for fibrin formation and platelet activation. Thrombin also plays both positive and negative regulatory roles in coagulation because of its pan-specific action on multiple coagulation proteins. These Developing an enzyme-based approach to prepare synthetic low-molecular-weight heparin
Jian Liu PhD
Low-molecular-weight heparin (LMWH) is clinically used to treat clotting disorders. As an animal-sourced product, LMWH's supply chain reliability is a concern for regulatory agencies. Here, we demonstrate the synthesis of heparin dodecasaccharides 
Platelet biogenesis in the lung circulation
Mark R. Looney MD
Platelets are indispensable in hemostasis, thrombosis, and immune responses. In humans, billions of platelets are produced each day from megakaryocytes, however the mechanisms of mature platelet production are incompletely understood. Historical data indicate that the lung may be a site of platelet biogenesis. Using intravital imaging in mice, 31 megakaryocytes were visualized releasing platelets in the lung circulation, and this process was responsible for approximately half of the mature platelet production in mice. 32 The mechanisms by which the lung circulation facilitates platelet biogenesis is a novel area of investigation for understanding platelet production defects. The lung may be a suitable bioreactor for the production of mature platelets from in vitro-derived megakaryocytes. 33 The lung also contains "resident" megakaryocytes and hematopoietic precursors, the latter being capable of migrating to the bone marrow to participate in the production of platelets and other mature hematopoietic lineages. 
Lung circulation
Regulation of von Willebrand factor function at the level of self-association
José A. López MD
Von Willebrand factor is the largest protein in blood plasma and has multiple roles in hemostasis, the best known of which is to mediate the attachment of platelets to the vessel wall, usually at sites of injury. In pathological states, VWF can remain attached to the vessel wall and allow platelets to attach to intact vascular endothelium. The ability of VWF to carry out its adhesive function is regulated by a number of factors, including the concentration of the protein, its mutimeric structure, and the degree to which it is proteolyzed by the plasma protease ADAMTS13. Less appreciated as important for VWF function is its ability to self−associate, taking already very long molecules and assembling them into strands of potentially prodigious sizes (see Platelet polyphosphate and factor XII (nature's way to engineer nanoparticles)
Coen Maas PhD
The contact system contributes to coagulation in vitro, but contact factor deficiencies do not cause bleeding. Remarkably, the contact system has a pronounced role in mouse thrombosis models. Here, platelet polyphosphate was proposed as the endogenous trigger for Factor XII (FXII) activation. 37, 38 This is surprising as short platelet polyphosphate polymers have limited potential for contact activation.
Contact system activators in clotting reagents are usually fine particulates. We found that platelets store and release polyphosphate in a comparable state as polyphosphate nanoparticles, which can be tracked with DAPI (membrane-permeant) and SYTOX (membrane-impermeant). 39 Polyphosphate nanoparticles remain on the platelet surface under flow, and can be isolated from platelet lysates. Platelet-sized polyphosphate efficiently triggers contact system activation as a nanoparticle state, but much less as a soluble polymer.
Extracellular polyphosphate is concentrated in the core of the thrombus, but not in the shell. This favors the concept that the contact system contributes to thrombus stability: once a thrombus is physically "threatened" and plasma reaches the thrombus core, FXII-driven thrombin formation is triggered to ensure thrombus stability. The platelet lifeline to cancer Anil K. Sood MD Platelets are well known to play important roles in hemostasis and wound remodeling and healing. However, the bidirectional interplay between platelets and cancer is increasingly recognized for its impact on tumor biology and patient outcomes.
Thrombocytosis, resulting from tumor-derived factors, occurs with varying frequency in cancer patients and is associated with adverse clinical outcomes. 46 Biologically, cancer is often considered analogous to a non-healing or chromic wound. There is growing evidence that platelets play key roles in many steps of tumor development and progression including proliferation, extravasation, survival, and metastasis. 47 Moreover, platelets may actively infiltrate into the tumor microenvironment and facilitate evasion from cancer therapies. 48 Understanding these complex interactions related to the roles of platelets in tumor biology offer new opportunities for reducing thrombosis, blocking tumor growth, and ultimately improving patient outcomes.
TF and cancer: blocking tissue factor signaling in breast cancer inhibits tumor metastasis
Henri H. Versteeg PhD
Tissue factor (TF) promotes breast cancer metastasis by activating coagulant pathways, 50,51 but the role of TF signaling in metastasis has never been addressed. We show that an antibody against TF that inhibits signaling uncouples TF from integrin a3b1 and leads to a net cellular increase in active integrin b1. In vitro, TF inhibition leads to a reduction in cancer stem cells (CSCs) and CSC effector molecules such as Sox9 and Slug. Such a link between TF and CSC is supported by an association between TF expression and the CSC marker aldehyde dehydrogenase 1 (ALDH1) in tumor specimens from 574 breast cancer patients. In vivo we show that inhibition of TF signaling inhibits metastasis 10-fold when given in a scheme that has little effect on primary tumor growth. Thus, TF signaling inhibition leads to a reduced CSC transcriptional program, a reduction in primary tumorresident cancer stem cells and a subsequent reduction in metastasis. 
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Tissue factor-independent inhibition of thrombin generation by TFPIα
Jeremy P. Wood PhD
The tissue factor (TF) pathway of thrombin generation, which commences when the TF/factor VIIa (FVIIa) complex activates the serine protease factor Xa (FXa), is inhibited by TF pathway inhibitor alpha (TFPIα) at three steps. First, two inhibitory domains of TFPIα (K1, K2) block FXa activation by TF/FVIIa. Second, TFPIα also inhibits the generated FXa by blocking its active site with K2. The cofactor protein S promotes and stabilizes this interaction. 58 Third, TFPIα inhibits prothrombinase, the thrombin-producing complex of FXa and factor Va (FVa), during the initiation of thrombin generation. 59 This inhibition requires that K2 binds the FXa active site and that the TFPIα basic C-terminus binds both a regulatory acidic region present in FXaactivated and platelet-released forms of FVa and the FVa heavy chain, an interaction which displaces FXa. 59,60 Through these TF-dependent and -independent activities, TFPIα establishes an activation threshold for the initiation of coagulation. 
